Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.
Abstract
Cancer patients spontaneously generate autoantibodies (AAb) to tumor-derived proteins. To detect AAb, we have probed novel high-density custom protein microarrays (NAPPA) expressing 4988 candidate tumor antigens with sera from patients with early stage breast cancer (IBC), and bound IgG was measured. We used a three-phase serial screening approach. First, a prescreen was performed to eliminate uninformative antigens. Sera from stage I-III IBC (n = 53) and healthy women (n = 53) were screened for AAb to all 4988 protein antigens. Antigens were selected if the 95th percentile of signal of cases and controls were significantly different (p < 0.05) and if the number of cases with signals above the 95th percentile of controls was significant (p < 0.05). These 761 antigens were screened using an independent set of IBC sera (n = 51) and sera from women with benign breast disease (BBD) (n = 39). From these, 119 antigens had a partial area under the ROC curve (p < 0.05), with sensitivities ranging from 9-40% at >91% specificity. Twenty-eight of these antigens were confirmed using an independent serum cohort (n = 51 cases/38 controls, p < 0.05). Using all 28 AAb, a classifier was identified with a sensitivity of 80.8% and a specificity of 61.6% (AUC = 0.756). These are potential biomarkers for the early detection of breast cancer.
Biomarkers
The following biomarkers make reference to this publication:
- ALG10
- ATF3
- ATP6AP1
- BDNF
- BMX
- C15orf48
- CSNK1E
- CTBP1
- DBT
- EIF3E
- FRS3
- GPANK1
- GPR157
- HOXD1
- MYOZ2
- PDCD6IP
- RAB5A
- RAC3
- SELL
- SERPINH1
- SF3A1
- SLC33A1
- SOX2
- TFCP2
- TRIM32
- UBAP1
- ZMYM6
- ZNF510
Protocols
One protocol is associated with this publication:
Authors
- Anderson KS
- Engstrom P
- Godwin AK
- Hainsworth E
- Labaer J
- Logvinenko T
- Lokko N
- Marks J
- Mendoza EA
- Montor WR
- Park JG
- Qiu J
- Ramachandran N
- Raphael J
- Sibani S
- Wallstrom G
- Wong J